3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 20...(GAAP GAAP Non-GAAP ...)

Date:3/11/2009

GAAP GAAP Non-GAAP Non-GAAP RMB US$ RMB RMB US$ Net income per share: Basic and diluted 0.26 0.04 0.49 0.07 Basic weighted average number of shares outstanding 151,655,631 151,655,631 151,655,631 151,655,631 Effect of dilutive potential shares 57,118 57,118 57,118 57,118 Diluted weighted average number of shares outstanding 151,712,749 151,712,749 151,712,749 151,712,749 Net income per ADS: Basic and diluted 1.82 0.27 3.46 0.51 Basic weighted average number of ADSs outstanding 21,665,090 21,665,090 21,665,090 21,665,090 Effect of dilutive potential ADSs 8,160 8,160 8,160 8,160 Diluted weighted average number of ADSs outstanding 21,673,250 21,673,250 21,673,250 21,673,250

Notes to reconciliation of our GAAP statements of to our adjusted non-GAAP statements of income:

    (1) To exclude share-based compensation expense.
    (2) To exclude one-time upfront payment for license fee of RMB6,948,000
        and share-based compensation expense of RMB 521,000 for R&D staff.
    (3) To exclude realized loss on available-for-sale securities.
    (4) To exclude impairment loss on available-for-sale securities.
    (5) No income tax effect on adjustments is required as they are
        incurred by overseas companies that are not subject to income tax.



    Year Ended December 31, 2007
    (unaudited)       Actual     Actual   Adjustment    Adjusted      Adjusted
                       GAAP       GAAP                  Non-GAAP      Non-GAAP
                       RMB         US$      RMB           RMB           US$
 
'/>"/>
SOURCE  3SBio Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Related biology technology :

1. 3SBio Inc. Receives Official Recognition as a High-Tech Enterprise
2. 3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009
3. 3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer
4. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
5. 3SBio Inc. Announces Third Quarter 2008 Results
6. 3SBio Inc. Files for SFDA Approval of NuLeusin
7. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
8. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
9. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
10. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
11. 3SBio Inc. Announces Results of Annual General Meeting